Deferasirox belongs to the class antidote, which is not official in any pharmacopoeia. But only a few reported studies were availableemploying RP-HPLC technique. To validate the analytical process, we chose bulk powder and tablets of different intensity deferasirox tablets.The objective of the research or analysis is to develop a sensitive reverse phase chromatography method and validate quantitative perseverance of deferasirox in bulk and marketed formulation. A Simple, precise, accurate, economical and reliable UVspectrometric method has been developed toestimate deferasirox bulk and its tablet dosage form. The method was validated as per the international conference on harmonization (ICHQ2AR1) the validated dosage type was tested for device suitability, precision, linearity, specificity, robustness, and ruggedness.Statistical analysis proved that the method is repeatable and specific for the determination of the said drug. The established procedure or technique was done using Inertsil ODS 3V (C18 250mm X 4.6mm, 5µm) column oven temperature 40°C and sample temperature is 8°C with a flow rate of 1.5mL/min. By using HPLC waters PU-2487 pump and photodiode array detector at 245nm. The separation was carried out using a mobile phase consisting of amixture of sodium di hydrogen phosphate monohydrate buffer (pH3.0) and acetonitrile in the ratio of 45:55. The retention time of Deferasirox peak was considered to be about 7.5 min and the total run time was found to be 20 minutes.The calibration plot gave linear relationship over the concentration range of 6.28- 811.480 µg/ml The average percent recovery was proved to be 96.1,97.6&103.The correlation coefficient was found to be 0.999. The relative standard deviation (R.S.D) was found <2.0% for the UV-spectroscopic RP-HPLC method. The percent assessment of the drug was around 100% indicating the accuracy of the procedure. The suggested techniques were further confirmed and employed for the testing of the drug in tablet preparation.

REFERENCES 

1. Chemblink[internet]deferasirox/Enter/productname/CAS#/formula or companyname/URL     https://www.chemblink.com/MSDS/201530-41-8_MSDS.htm
2. Tripathy KD. Essentials of medical pharmacology. Jaypee Publishers. 7th ed. N Delhi: Acedemic press; 2013.p.. 599.
3. Manzoori JL, Jouyban A, Amjadi M, Panahi-Azar V, Tamizi E, Vaez-Gharamaleki J. Terbium sensitized fluorescence method for the determination of deferasirox in biological fluids and tablet formulation. Luminescence. 2011;26(4):244-50. doi: 10.1002/bio.1218, PMID 21830288.
4. Chakravarthy VK, Gowrisankar D. LC determination of deferasirox in pharmaceutical formulation. J Glob Trends Pharm Sci. 2010;1:37-45.
5. Kaja RK, Surendranath KV, Radhakrishnanand P, Satish J, Satyanarayana PVV. A stability indicating LC method for deferasirox in bulk drugs and pharmaceutical dosage forms. Chromatographia. 2010;72(5-6):441-6. doi: 10.1365/s10337-009-1023-1.
6. Séchaud R, Dutreix C, Balez S, Pommier F, Dumortier T, Morisson S, Brun E. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J ClinPharmacolTher. 2008;46(2):102-8. doi: 10.5414/cpp46102, PMID 18218291.
7. Bruin GJM, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, Waldmeier F. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug MetabDispos. 2008;36(12):2523-38. doi: 10.1124/dmd.108.022962, PMID 18775980.
8. Anandakumar K, Ramu C, Subhash V, Jayamariappan M. Development and validation of newer analytical methods for the estimation of deferasirox in bulk and in tablet dosage form by UV spectroscopy and RP-HPLC. J Pharm Res. 2011;4(9):2998-3000.
9. Somisetty VSR, Dhachinamoorthi D, Rahaman SA, Rao CHMMP. Development and validation of newer analytical methods for the estimation of deferasirox in bulk and in tablet dosage form by UV spectroscopy and RPHPLC. Development. 2013;5:1861.
10. Padmaja N, Ramathilagam N. Method development and validation of RP-HPLC method for the determination of deferasirox in tablets. Int J Pharm Biol Sci. 2012;2:338.
11. Asian Guideline for Validation of Analytical Procedure Adopted from ICH guideline, Q2A27; Oct 1994 and ICH. 1994;Q2B(v) 6.
12. ICH, Topic Q. 2, Validation of Analytical Procedures, Text and Methodology European Medicines Agency West ferry Circus, Canary Wharf, London. Vol. E14. UK (v). p. 4HB.
13. International Conference on Harmonization. Guidance to Industry: Q2B Validation of Analytical      Procedure. Center for Drug Evaluation and Research, Rockville, MD. 2000, 1-11.
14. United States Pharmacopeia Convention. United States Pharmacopoeia (USP) 25. USP, Rockville, MD, 2002, pp. 8-70, 274-75.
15. Marathe GM, Pande VV, Patil PH, Mutha RE, Bari SB. Quantitative determination of deferasirox in bulk and pharmaceutical formulation by UV spectrophotometric method. Indian Drugs. 2013;50:2.
16. SarsambiPrakash S, Chaitanya S, Prasanna KL. Development and validation of new Spetrophotometric methods for the estimation of deferasirox in bulk drug and its formulations using 1,10-phenanthroline and MBTH reagents. Unique res. J Chem. 2013;1:47.
17. Gower JD, Healing G, Green CJ. Determination of desferrioxamine-available iron in biological tissues by high-pressure liquid chromatography. Anal Biochem. 1989;180(1):126-30. doi: 10.1016/0003-2697(89)90099-7, PMID 2817334.
18. Ahmed M, Jangade V, Shetty S, Aradhya VC, Kuppast IJ, Kumar A. Development and validation of first order derivative spectrophotometric method for the estimation of deferiprone in bulk and capsule dosage form. Int J Univ Pharm Life Sci. 2015;4:169.
19. Hayes DM, Reilly RM, Lee MMC. The pharmaceutical stability of DeferoxamineMesylate. Can J Hosp Pharm. 1994;47:9.